Treatment for glioblastoma (GBM)
Intended for US audiences only.
Optune® Novocure™

Website privacy policy

Novocure recognizes the importance of protecting the privacy of the users of its website. The information about you collected on this website is subject to this policy and the following paragraphs. Novocure may change this policy from time to time, so please revisit this privacy policy to be sure that you are familiar with its current policies.

Collection and Use of Information

Personally Identifiable Information

Novocure collects personally identifiable information (information that can be used to identify an individual) such as name, address, telephone number, email address or other information only when you voluntarily submit it to Novocure, such as when you email a question or request or submit a form for more information. Novocure will use this information to respond to requests for information and may use this information to contact you and provide you with information about our products. Novocure may also request that you provide us with demographic information (such as gender and age) or other information (such as medical condition or treatment information) that Novocure uses to help serve you better.

Non-Personally Identifiable Information

Novocure may also collect non-personally identifiable information (information that does not identify a specific individual) relating to such matters as: the number of visits to the website, the number of visitors to each page of the website, visitors' internet protocol (IP) addresses, and time spent on the website. Novocure uses this information, in aggregate form, to understand how visitors use the website so that Novocure can make improvements. Novocure may also use your IP address to help diagnose problems with servers and for purposes of system administration.


The use of cookies is now industry standard and they are used by most major websites, including Novocure's website. A cookie is a piece of data stored on a user's hard drive containing information about the user. Cookies can also enable Novocure to track the interests of users to enhance their experience on this website, and to deliver content specific to a user's interests. Novocure may place a cookie in the browser file of your computer and use similar technologies to communicate with cookies. You are always free to decline Novocure's cookie, and you may still use the site; however, some parts of the site may not work properly for you.

Information Sharing

Except as otherwise disclosed in this privacy policy, Novocure will not sell, rent, or distribute personally identifiable information we collect to any third party, unless we obtain your permission by at least giving you the opportunity to opt out of any such sharing. We may, however, share your personally identifiable information without permission or further notice with our affiliates, business partners (as described below), or others who work for us such as service providers, vendors, contractors, and agents. To the extent you submit personally identifiable information related to a specific initiative or campaign, we may share the information with any subsequently formed affiliate dedicated to such initiative or campaign. Novocure may share non-personally identifiable information with agents, business partners, consultants or other outside companies.

We may partner with other companies to provide or offer you content or services on a joint or cobranded basis. At a cobranded site or in joint marketing materials, you would likely see both the Novocure logo and the logo of the cobranded partner displayed on your screen. To access the services available on a cobranded site, you may have to complete a new online registration form, and this registration information may be shared with Novocure and Novocure's cobranded partners. You should read the individual privacy policies of our cobranded partners, as these may differ in some respects from ours. Reading these policies will help you to make an informed decision about whether to provide your information to a given site. You may opt out of sharing your information with a partner site by choosing not to use the service or content provided by the cobranded site.

To the extent permitted by law, any personally identifiable information or other information collected over our website or concerning its use, including the content of any communication you submit or post to any interactive features on the website (personally identifiable or not), may be disclosed to government authorities or third parties pursuant to a governmental investigation, legal request, subpoena, or other legal process. We also may share information with the government even without a request pursuant to regulatory reporting requirements. In addition, we may also use or disclose your information as permitted by law to enforce our rights, fight fraud, or protect the rights or property of Novocure, our affiliates, our patients, our website, its users, or third parties, or when we otherwise believe in good faith that the law requires it.

Corporate Change of Control or Sale of Assets

In the event of a corporate change in control resulting from, for example, a sale to or merger with another entity, or in the event of a sale of assets or a bankruptcy, Novocure reserves the right to transfer your personally identifiable information to the new party in control or the party acquiring assets.


Novocure does not knowingly collect any personal information from anyone under the age of 18, nor does Novocure knowingly market its website to anyone under the age of 18.


Please be advised that although Novocure has tried to create a secure and reliable site, the confidentiality of any communication or material transmitted to or from this website cannot be guaranteed. Novocure urges you to always exercise caution when conveying personal information over the internet.

When disclosing any personally identifiable information, you should remain mindful that such information might be accessible by the public and, consequently, may be collected and used by others without your consent. You should also recognize that your use of the internet and this site is solely at your own risk.

Changes to this Privacy Policy

Novocure reserves the right, in its sole discretion, to modify, alter or otherwise update this policy at any time and you agree to be bound by such modifications, alterations, or updates. We will notify you of material changes to this privacy policy by posting the revised policy with the date it was revised on this page. Your continued use of our website constitutes your agreement to this privacy statement and any updates. We encourage you to periodically review this privacy statement to stay informed about how we are using the personally identifiable information we collect.

Questions or Concerns

If you have other questions or concerns about our privacy policies or information usage, or wish to change any choices offered about how your information is handled or shared, email us at

Effective Date: April 7, 2014



Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).

Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery and completion of radiation therapy together with concomitant standard of care chemotherapy.

For the treatment of recurrent GBM, Optune is indicated following histologically-or radiologically-confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The device is intended to be used as a monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

Important Safety Information


Do not use Optune if you have an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune if you are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions

Use Optune only after receiving training from qualified personnel, such as your doctor, a nurse, or other medical personnel who have completed a training course given by Novocure (the device manufacturer).

Do not use Optune if you are pregnant, you think you might be pregnant or are trying to get pregnant. It is not known if Optune is safe or effective in these populations.

The most common (≥10%) adverse events involving Optune in combination with temozolomide were low blood platelet count, nausea, constipation, vomiting, fatigue, scalp irritation from device use, headache, convulsions, and depression.

The most common (≥10%) adverse events seen when using Optune alone were scalp irritation from device use and headache.

The following adverse reactions were considered related to Optune when using the device alone: scalp irritation from device use, headache, malaise, muscle twitching, fall and skin ulcer.

All servicing procedures must be performed by qualified and trained personnel.

Do not use any parts that do not come with the Optune Treatment Kit, or that were not sent to you by the device manufacturer or given to you by your doctor.

Do not wet the device or transducer arrays.

If you have an underlying serious skin condition on the scalp, discuss with your doctor whether this may prevent or temporarily interfere with Optune treatment.

Please click here to see the Optune Instructions For Use (IFU) for complete information regarding the device's indications, contraindications, warnings, and precautions.

Patient Journey videos on this site depict actual patients and caregivers. All other depictions of patients, caregivers, and healthcare professionals are actor portrayals.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).